Clinical Trials Logo
  1. Home
  2. Stargardt Disease 1
  3. NCT05674058

Function and Imaging Assessments for G1961E-associated Stargardt Disease — FIRSTORBIT  

Stargardt Disease Clinical Trial

Official title:
Function and Imaging Assessments for G1961E-associated Stargardt Disease: Outcome Measure Ranking as Basis for Interventional Trials

Clinical Trial Summary

Some phenotypes of Stargardt disease are rather distinct. This includes the 'bull's eye maculopathy' phenotype associated with the frequent ABCA4 G1961E variant. In anticipation of a treatment trial, this natural history study aims to compare functional and structural outcome measures systematically.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05674058
Study type Observational
Source Institute of Molecular and Clinical Ophthalmology Basel
Contact Maximilian Pfau, MD
Phone +41 79 525 92 47
Email maximilian.pfau@usb.ch
Status Recruiting
Phase
Start date November 1, 2022
Completion date October 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01676766 - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease N/A
Enrolling by invitation NCT06048185 - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Completed NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease Phase 3
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Completed NCT04909398 - Pupil Dynamics and Color Vision for the Detection of Eye Diseases N/A
Completed NCT02255981 - Efficacy of Acupuncture in Macular Diseases N/A
Completed NCT05266014 - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Phase 2
Terminated NCT02875704 - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Phase 2
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT02410122 - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation NCT04239625 - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) Phase 2
Recruiting NCT05956626 - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease Phase 1/Phase 2
Recruiting NCT02402660 - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2
Completed NCT01977846 - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Completed NCT05904444 - The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies N/A
Completed NCT02230228 - Phase 1 Safety Study of ALK-001 in Healthy Volunteers Phase 1
Not yet recruiting NCT06319872 - The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration Phase 1